Thermo Fisher Scientific (NYSE:TMO) Updates FY 2026 Earnings Guidance

Thermo Fisher Scientific (NYSE:TMO) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 24.930-25.330 for the period, compared to the consensus EPS estimate of 24.850. The company issued revenue guidance of $47.4 billion-$48.1 billion, compared to the consensus revenue estimate of $47.8 billion.

Thermo Fisher Scientific Price Performance

TMO stock traded up $49.43 during trading on Thursday, hitting $575.89. The stock had a trading volume of 2,124,990 shares, compared to its average volume of 2,306,281. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The company’s 50-day moving average price is $488.92 and its two-hundred day moving average price is $513.21. The stock has a market capitalization of $214.01 billion, a P/E ratio of 31.59, a PEG ratio of 2.32 and a beta of 0.87. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts predict that Thermo Fisher Scientific will post 24.84 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TMO. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. HSBC downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their target price for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Barclays reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Royal Bank Of Canada set a $490.00 price target on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a report on Thursday, May 14th. Finally, Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $602.14.

Insider Activity

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Thermo Fisher beat Q2 expectations, posting $6.03 adjusted EPS versus the $5.71 consensus and $11.99 billion in revenue versus $11.71 billion expected, helped by stronger customer activity across end markets and continued organic growth. Article Title
• Positive Sentiment: The company also raised FY2026 guidance, now calling for EPS of $24.93 to $25.33 and revenue of $47.4 billion to $48.1 billion, both above Wall Street estimates, which suggests management is seeing a healthier operating backdrop.
• Positive Sentiment: Earlier reports noted shares rose in premarket trading after the earnings beat, reflecting investor optimism that demand is improving across Thermo Fisher’s life sciences, diagnostics, and lab equipment businesses. Article Title
• Neutral Sentiment: ImmuPharma selected Thermo Fisher’s Patheon unit to manufacture its Kapiglucagon diabetes candidate, a modest business-development win that adds some incremental contract manufacturing exposure but is unlikely to move the stock on its own. Article Title

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Revolve Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. lifted its stake in Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after buying an additional 20 shares during the last quarter. Challenger Wealth Management boosted its holdings in shares of Thermo Fisher Scientific by 3.1% in the second quarter. Challenger Wealth Management now owns 735 shares of the medical research company’s stock valued at $298,000 after acquiring an additional 22 shares during the period. Security National Bank of Sioux City Iowa IA increased its holdings in shares of Thermo Fisher Scientific by 0.3% in the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 6,549 shares of the medical research company’s stock valued at $2,655,000 after acquiring an additional 22 shares during the period. Finally, Johnson Financial Group Inc. raised its position in Thermo Fisher Scientific by 1.3% in the 4th quarter. Johnson Financial Group Inc. now owns 1,746 shares of the medical research company’s stock valued at $1,012,000 after purchasing an additional 22 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.